symbol,statement_type,period_end,line_item,value
THEMISMED.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
THEMISMED.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.248069
THEMISMED.NS,income,2025-03-31 00:00:00,Normalized EBITDA,596431000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Total Unusual Items,
THEMISMED.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
THEMISMED.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,298330000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,99287000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,1319906000.0
THEMISMED.NS,income,2025-03-31 00:00:00,EBITDA,596431000.0
THEMISMED.NS,income,2025-03-31 00:00:00,EBIT,497144000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Net Interest Income,-100395000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Interest Expense,100395000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Interest Income,
THEMISMED.NS,income,2025-03-31 00:00:00,Normalized Income,298330000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,298330000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Total Expenses,3663921000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
THEMISMED.NS,income,2025-03-31 00:00:00,Diluted Average Shares,92077160.0
THEMISMED.NS,income,2025-03-31 00:00:00,Basic Average Shares,92077160.0
THEMISMED.NS,income,2025-03-31 00:00:00,Diluted EPS,3.24
THEMISMED.NS,income,2025-03-31 00:00:00,Basic EPS,3.24
THEMISMED.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,298330000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Average Dilution Earnings,
THEMISMED.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,298330000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
THEMISMED.NS,income,2025-03-31 00:00:00,Net Income,298330000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Minority Interests,2000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,298328000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,298328000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Tax Provision,98421000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Pretax Income,396749000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,46695000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Special Income Charges,
THEMISMED.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-100395000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
THEMISMED.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,100395000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
THEMISMED.NS,income,2025-03-31 00:00:00,Operating Income,391195000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Operating Expense,2344015000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Other Operating Expenses,1280970000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,99287000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Amortization,
THEMISMED.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,99287000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Selling General And Administration,
THEMISMED.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
THEMISMED.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
THEMISMED.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
THEMISMED.NS,income,2025-03-31 00:00:00,Gross Profit,2735210000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Cost Of Revenue,1319906000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Total Revenue,4055116000.0
THEMISMED.NS,income,2025-03-31 00:00:00,Operating Revenue,4055116000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
THEMISMED.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.185612
THEMISMED.NS,income,2024-03-31 00:00:00,Normalized EBITDA,750661000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Total Unusual Items,0.0
THEMISMED.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
THEMISMED.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,435238000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,122463000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,1367137000.0
THEMISMED.NS,income,2024-03-31 00:00:00,EBITDA,750661000.0
THEMISMED.NS,income,2024-03-31 00:00:00,EBIT,628198000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Net Interest Income,-93766000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Interest Expense,93766000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Interest Income,8393000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Normalized Income,435238000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,435238000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Total Expenses,3425019000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,21692000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Diluted Average Shares,92211441.0
THEMISMED.NS,income,2024-03-31 00:00:00,Basic Average Shares,92016490.0
THEMISMED.NS,income,2024-03-31 00:00:00,Diluted EPS,4.72
THEMISMED.NS,income,2024-03-31 00:00:00,Basic EPS,4.73
THEMISMED.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,435238000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Average Dilution Earnings,0.0
THEMISMED.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,435238000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
THEMISMED.NS,income,2024-03-31 00:00:00,Net Income,435238000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Minority Interests,3000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,435235000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,435235000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Tax Provision,99197000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Pretax Income,534432000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,47555000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Special Income Charges,0.0
THEMISMED.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-93766000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,17491000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,93766000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,8393000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Operating Income,392589000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Operating Expense,2057882000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Other Operating Expenses,1111315000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,122463000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Amortization,2184000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,122463000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Selling General And Administration,332569000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,223590000.0
THEMISMED.NS,income,2024-03-31 00:00:00,General And Administrative Expense,108979000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,21692000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Gross Profit,2450471000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Cost Of Revenue,1367137000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Total Revenue,3817608000.0
THEMISMED.NS,income,2024-03-31 00:00:00,Operating Revenue,3817608000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,113905.678695
THEMISMED.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.215323
THEMISMED.NS,income,2023-03-31 00:00:00,Normalized EBITDA,909470000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Total Unusual Items,529000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,529000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,569010000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,104948000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,1209968000.0
THEMISMED.NS,income,2023-03-31 00:00:00,EBITDA,909999000.0
THEMISMED.NS,income,2023-03-31 00:00:00,EBIT,805051000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Net Interest Income,-90171000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Interest Expense,79902000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Interest Income,5473000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Normalized Income,568594905.678695
THEMISMED.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,569010000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Total Expenses,2874989000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,18077000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Diluted Average Shares,92180107.0
THEMISMED.NS,income,2023-03-31 00:00:00,Basic Average Shares,92027700.0
THEMISMED.NS,income,2023-03-31 00:00:00,Diluted EPS,6.17
THEMISMED.NS,income,2023-03-31 00:00:00,Basic EPS,6.18
THEMISMED.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,569008000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Average Dilution Earnings,0.0
THEMISMED.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,569010000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
THEMISMED.NS,income,2023-03-31 00:00:00,Net Income,569010000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Minority Interests,2000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,569008000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,569008000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Tax Provision,156141000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Pretax Income,725149000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,34726000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Special Income Charges,0.0
THEMISMED.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,-90171000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,15742000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,79902000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,5473000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Operating Income,569561000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Operating Expense,1665021000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Other Operating Expenses,715479000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,104948000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Amortization,2184000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,102764000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Selling General And Administration,263747000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,170302000.0
THEMISMED.NS,income,2023-03-31 00:00:00,General And Administrative Expense,93445000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,18077000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Gross Profit,2234582000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Cost Of Revenue,1209968000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Total Revenue,3444550000.0
THEMISMED.NS,income,2023-03-31 00:00:00,Operating Revenue,3444550000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,79646.246142
THEMISMED.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.234945
THEMISMED.NS,income,2022-03-31 00:00:00,Normalized EBITDA,1112448000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Total Unusual Items,339000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,339000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,728808000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,94798000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,1519946000.0
THEMISMED.NS,income,2022-03-31 00:00:00,EBITDA,1112787000.0
THEMISMED.NS,income,2022-03-31 00:00:00,EBIT,1017989000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Net Interest Income,-81690000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Interest Expense,65369000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Interest Income,6055000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Normalized Income,728548646.246142
THEMISMED.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,728808000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Total Expenses,3051928000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,9794000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Diluted Average Shares,92175350.0
THEMISMED.NS,income,2022-03-31 00:00:00,Basic Average Shares,92002700.0
THEMISMED.NS,income,2022-03-31 00:00:00,Diluted EPS,7.907
THEMISMED.NS,income,2022-03-31 00:00:00,Basic EPS,7.922
THEMISMED.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,728808000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Average Dilution Earnings,
THEMISMED.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,728808000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
THEMISMED.NS,income,2022-03-31 00:00:00,Net Income,728808000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Minority Interests,1000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,728807000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,728807000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Tax Provision,223813000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Pretax Income,952620000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,12646000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Special Income Charges,0.0
THEMISMED.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-81690000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,22376000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,65369000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,6055000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Operating Income,861552000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Operating Expense,1531982000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Other Operating Expenses,661814000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,94798000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Amortization,2184000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,92614000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Selling General And Administration,278512000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,179291000.0
THEMISMED.NS,income,2022-03-31 00:00:00,General And Administrative Expense,99221000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,9794000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Gross Profit,2393534000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Cost Of Revenue,1519946000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Total Revenue,3913480000.0
THEMISMED.NS,income,2022-03-31 00:00:00,Operating Revenue,3913480000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
THEMISMED.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
THEMISMED.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
THEMISMED.NS,income,2021-03-31 00:00:00,Total Unusual Items,188000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,188000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
THEMISMED.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
THEMISMED.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
THEMISMED.NS,income,2021-03-31 00:00:00,EBITDA,
THEMISMED.NS,income,2021-03-31 00:00:00,EBIT,
THEMISMED.NS,income,2021-03-31 00:00:00,Net Interest Income,
THEMISMED.NS,income,2021-03-31 00:00:00,Interest Expense,
THEMISMED.NS,income,2021-03-31 00:00:00,Interest Income,4121000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Normalized Income,
THEMISMED.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
THEMISMED.NS,income,2021-03-31 00:00:00,Total Expenses,
THEMISMED.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,8338000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Diluted Average Shares,
THEMISMED.NS,income,2021-03-31 00:00:00,Basic Average Shares,
THEMISMED.NS,income,2021-03-31 00:00:00,Diluted EPS,
THEMISMED.NS,income,2021-03-31 00:00:00,Basic EPS,
THEMISMED.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
THEMISMED.NS,income,2021-03-31 00:00:00,Average Dilution Earnings,
THEMISMED.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
THEMISMED.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
THEMISMED.NS,income,2021-03-31 00:00:00,Net Income,
THEMISMED.NS,income,2021-03-31 00:00:00,Minority Interests,
THEMISMED.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
THEMISMED.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
THEMISMED.NS,income,2021-03-31 00:00:00,Tax Provision,
THEMISMED.NS,income,2021-03-31 00:00:00,Pretax Income,
THEMISMED.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
THEMISMED.NS,income,2021-03-31 00:00:00,Special Income Charges,0.0
THEMISMED.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
THEMISMED.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,17468000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
THEMISMED.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,4121000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Operating Income,
THEMISMED.NS,income,2021-03-31 00:00:00,Operating Expense,
THEMISMED.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
THEMISMED.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
THEMISMED.NS,income,2021-03-31 00:00:00,Amortization,2184000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
THEMISMED.NS,income,2021-03-31 00:00:00,Selling General And Administration,161568000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,94715000.0
THEMISMED.NS,income,2021-03-31 00:00:00,General And Administrative Expense,66853000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,8338000.0
THEMISMED.NS,income,2021-03-31 00:00:00,Gross Profit,
THEMISMED.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
THEMISMED.NS,income,2021-03-31 00:00:00,Total Revenue,
THEMISMED.NS,income,2021-03-31 00:00:00,Operating Revenue,
